Behavioral Health · Psychedelics

Psychedelics in Oregon: from psilocybin services to evidence-based recovery care

Oregon already has the nation’s first state-regulated psilocybin service system. The next question is not whether psychedelics are interesting. It is how to separate evidence from hype and determine whether carefully supervised psychedelic-assisted care can responsibly fit into mental-health and addiction treatment.

Published October 3, 2026Field note

Important: This is a policy and research note, not medical advice. Psychedelic drugs can carry serious medical and psychiatric risks. For opioid-use disorder, established medications such as buprenorphine and methadone save lives and should not be withheld or stopped in favor of an experimental psychedelic treatment.

Oregon has already built something unusual

Oregon voters approved Measure 109 in 2020, now codified as ORS 475A. The state created a regulated system for adults 21 and older to receive psilocybin services. It is not a dispensary model: clients complete a preparation session, consume psilocybin at a licensed service center, remain there during an administration session with a licensed facilitator, and may participate in integration afterward. A prescription or medical referral is not required.

That distinction matters. Oregon’s current system is a regulated health-and-wellness service model, not the same thing as a medical treatment program for depression, PTSD, opioid-use disorder, or another diagnosis.

The system is no longer hypothetical. Oregon Health Authority data for 2025 report 5,935 clients served, including 4,628 individual administration sessions and 747 group administration sessions. The same year-end dashboard reported 25 instances, measured from the beginning of regulated services through the end of 2025, in which service centers contacted emergency services. Those numbers provide useful safety and utilization information, but they do not by themselves establish that psilocybin treats any particular disorder.

The system is changing in 2026

Oregon has been trying to close some of the gap between the wellness model and conventional health care. House Bill 2387, enacted in 2025, allows certain licensed health professionals who also hold an Oregon psilocybin facilitator license to conduct preparation and integration sessions under both professional licenses beginning in 2026. That creates a clearer path for appropriately licensed clinicians to bring their existing professional scope into parts of psilocybin care without simply declaring the entire psilocybin system to be medical treatment.

Oregon Psilocybin Services also went through another major rulemaking process in 2026. OHA proposed significant fee changes, received public and advisory-board feedback, and ultimately announced that it would not adopt the proposed fee increases. OHA says a new round of rulemaking on non-fee issues is expected to target a January 15, 2027 effective date.

What about psychedelics other than psilocybin?

ORS 475A creates a regulated service-center framework specifically for psilocybin. It does not create comparable Oregon service-center access to MDMA, LSD, ibogaine, or other psychedelic compounds.

Ibogaine is the other drug drawing especially serious attention because of its potential relevance to addiction. Oregon lawmakers considered HB 3817 in 2025, which was amended into a proposal for OHA and the Oregon Department of Veterans’ Affairs to study ibogaine. In 2026, HB 4110 proposed allowing an attending physician to provide ibogaine to eligible patients for certain mental-health or substance-use disorders in a controlled setting with cardiac expertise available. The Oregon Legislative Information System currently shows HB 4110 in the House Committee on Behavioral Health and no chapter number, meaning it has not become Oregon law.

At the federal level, the landscape is also moving. In 2026 the FDA finalized guidance for clinical investigations of psychedelic drugs, issued priority-review support for several psychedelic-development programs, and allowed an early-phase study of noribogaine (the principal active metabolite of ibogaine) to move forward under an Investigational New Drug application. The FDA also held a September 2026 public hearing focused on possible future therapeutic use of psychedelic drugs in supervised settings. Psilocybin nevertheless remains a Schedule I substance under federal law.

What does the evidence actually show?

The strongest modern clinical evidence is not the same for every psychedelic or every condition.

Depression: randomized trials have found rapid reductions in depressive symptoms after psilocybin administered with psychological support. A 2023 JAMA trial of 104 adults with major depressive disorder found significantly larger reductions in depression scores with a single 25-mg psilocybin session than with niacin placebo through six weeks. A 2026 randomized trial also found a significant early antidepressant effect, with some secondary differences lasting beyond three months, but no significant between-group difference at one year; two participants in the psilocybin group experienced persistent severe anxiety requiring medical attention.

Alcohol-use disorder: a randomized JAMA Psychiatry trial found that psilocybin combined with psychotherapy reduced the percentage of heavy-drinking days compared with active placebo plus psychotherapy. That is meaningful evidence for continued research, but the study also had limitations, including difficulty maintaining blinding and limited ability to generalize to more medically or psychiatrically complex patients.

Opioid-use disorder: this is where caution is especially important. There is scientific interest in psychedelics, particularly ibogaine and noribogaine, for withdrawal, craving, and addiction-related behavior. But a 2026 literature review concluded that no double-blind randomized trial had yet demonstrated that ibogaine or noribogaine effectively treats opioid-use disorder. The positive human evidence remains largely observational, open-label, retrospective, or otherwise exploratory.

Ibogaine has a safety problem that cannot be hand-waved away

Ibogaine has been associated with clinically important QT-interval prolongation and potentially fatal ventricular arrhythmias. A 2026 review in Addiction concluded that these events can occur even at treatment-range exposure and in people without known pre-existing heart disease. Other clinical reports have documented marked QT prolongation during detoxification studies.

That does not mean ibogaine should never be studied. It means that any serious Oregon discussion has to treat it as an experimental medical intervention with a materially different risk profile from Oregon’s existing psilocybin wellness model. A legitimate clinical study would need physician oversight, medication-interaction review, laboratory screening, continuous or repeated cardiac monitoring as appropriate, emergency capability, standardized pharmaceutical-grade product, and independent safety review. It should not be offered as an informal detox shortcut.

Oregon’s opioid crisis is improving, but it is not over

Oregon Health Authority reported in May 2026 that overdose deaths had declined for two consecutive years. The state recorded 1,544 overdose deaths in 2024, down from 1,833 in 2023, and provisional federal data suggested roughly 1,100 deaths in 2025. OHA also reported that more than 90% of reported overdose deaths involved fentanyl, methamphetamine, or a combination of the two. In 2024, 62.2% of overdose deaths involved multiple substances.

That reality argues against building an addiction strategy around any single drug, psychedelic or otherwise.

For opioid-use disorder, Oregon Health Authority and SAMHSA identify methadone, buprenorphine, and naltrexone as evidence-based medications. OHA describes medication for opioid-use disorder as the gold standard, associated with less illicit opioid use, better treatment outcomes, and lower use of emergency departments. Any psychedelic research program focused on opioid addiction should therefore be designed as an adjunct to evidence-based care, not a replacement for it.

A clinical psychedelic-assisted recovery pilot Oregon could evaluate

There is a meaningful policy space between two extremes: treating psychedelics as miracle cures, or refusing to investigate them at all. A rigorous Oregon pilot could test where these therapies fit while protecting patients and preserving treatments that already have strong evidence.

1. Keep the clinical pilot separate from the wellness market

Oregon’s current psilocybin service system can continue serving adults under ORS 475A. A treatment-and-recovery pilot should have a separate clinical framework, with medical governance, defined diagnoses or study populations, stronger screening, outcome measurement, and formal adverse-event review. The state should not quietly convert every licensed service center into an addiction clinic.

2. Use different evidence gates for different drugs and conditions

Psilocybin for depression has a different evidence base than ibogaine for opioid-use disorder. Alcohol-use disorder has different evidence again. A pilot should specify which interventions are mature enough for pragmatic clinical research and which remain early-stage investigational work. Ibogaine or noribogaine should remain in an FDA-authorized research pathway unless stronger safety and efficacy evidence justifies something broader.

3. Never force people off established opioid treatment

Participation should not require a person to abandon buprenorphine, methadone, naltrexone, naloxone access, counseling, pain treatment, or other evidence-based care. Medication changes should be based on individualized clinical judgment and safety, not ideology about what “real recovery” is supposed to look like.

4. Build an actual continuum of recovery around the psychedelic session

The intervention should not be one dramatic day followed by a bus ticket home. A serious program would connect screening and preparation with ongoing behavioral-health care, primary care, addiction medicine, peer recovery support, family support when wanted, housing navigation, employment and education services, pain management, and long-term follow-up. For many people, those social conditions are part of whether recovery can last.

5. Use multidisciplinary teams

A clinical program should bring together appropriately licensed behavioral-health clinicians, addiction-medicine expertise, medical staff, trained psychedelic facilitators where relevant, peer-recovery specialists, pharmacists or medication experts, and emergency support. Dual licensure under Oregon’s newer psilocybin law can help create bridges between professional clinical care and the facilitator system, but scope-of-practice boundaries still matter.

6. Screen seriously for medical and psychiatric risk

Modern psychedelic trials commonly exclude or closely manage people with conditions that could increase risk, including some histories of psychosis or mania, acute suicidality, unstable medical illness, and interacting medications. The exact criteria should follow the intervention and the evidence. Ibogaine-related research would require particularly strong cardiac risk management.

7. Measure outcomes that matter

A state pilot should publicly track more than whether somebody completed a dosing session. Outcomes could include depression and anxiety symptoms, substance use, retention in opioid medication treatment, overdose and emergency-care utilization, quality of life, housing stability, employment or education participation, treatment retention, adverse events, and patient-reported recovery. Outcomes should be followed for months, not days.

8. Make the data public and independently evaluated

Oregon already created a public psilocybin data dashboard. A clinical pilot should go further: preregister evaluation plans, publish aggregate outcomes, make adverse-event definitions transparent, use independent academic and ethics review, and compare outcomes against appropriate control or usual-care groups where feasible. OHSU, Oregon universities, tribal health partners, community providers, and independent researchers could all have roles, but no single commercial psychedelic company should control the evidence.

9. Treat affordability and geography as design problems

A program that is clinically promising but available only to people who can pay thousands of dollars out of pocket is not a statewide behavioral-health strategy. Any pilot should measure cost, workforce requirements, rural access, travel burden, and whether low-income Oregonians can actually participate. State-only pilot funding, research grants, and other legally permissible mechanisms can be evaluated while federal controlled-substance and Medicaid restrictions remain relevant.

10. No coercive psychedelic treatment

Participation should be voluntary. Courts, probation systems, employers, schools, or family members should not be able to compel someone into a psychedelic session. Informed consent should address realistic benefits, uncertainty, known risks, alternatives, privacy, the right to stop, and what happens if a participant experiences a prolonged adverse reaction.

11. Respect Indigenous knowledge without extracting from it

Many psychedelic traditions predate modern pharmaceutical research by generations or centuries. Oregon should distinguish clinical evidence from cultural claims while involving Indigenous communities where appropriate and avoiding the assumption that traditional practices exist simply as raw material for commercial drug development.

The goal should be better care, not a psychedelic brand

A useful behavioral-health system is not “pro-psychedelic” or “anti-psychedelic.” It asks the same questions of these drugs that it should ask of any intervention: Does it work? For whom? Compared with what? How durable is the benefit? What can go wrong? Who is excluded from the evidence? What does it cost? And what safeguards are necessary?

Oregon is in a rare position. It has several years of real-world regulated psilocybin experience, a growing public data system, clinicians beginning to work under dual licenses, an active state debate about ibogaine, and a federal government that is now accelerating psychedelic research. At the same time, the state still faces serious mental-health access problems and an overdose crisis that continues to take roughly a thousand lives a year.

The next phase should be about connecting those facts carefully: preserving Oregon’s existing psilocybin framework, expanding rigorous research, testing clinically integrated models, protecting access to proven addiction medications, and refusing to promise more than the evidence can support.

See the developing Health section of the agenda →